

OBSERVATIONS

U-Shaped Association Between White Blood Cell Count and Fasting Plasma Glucose Level

It is well known that hyperglycemia is associated with increased mortality from cardiovascular disease (CVD) and all-cause mortality. It has recently been reported that subjects with low fasting plasma glucose (FPG) levels also had a high risk of CVD and all-cause mortality (1). However, there is a paucity of information about the etiologic basis underlying the association between low FPG and increased CVD and all-cause mortality. Thus, in the present study, we investigated the association of FPG levels with white blood cell (WBC) counts, which indicate a state of low-grade systemic inflammation.

We investigated the cross-sectional association of WBC counts with FPG levels among 3,256 Japanese men aged 34–69 years. The subjects were divided into six categories according to FPG level: <80 mg/dl, 80 to <90 mg/dl, 90 to <100 mg/dl, 100 to <110 mg/dl, 110 to <126 mg/dl, and diabetes.

The crude mean WBC counts were 6,409, 6,308, 6,111, 6,111, 6,109, and 6,610 cells/mm³ in the subjects with FPG levels of <80 mg/dl, 80 to <90 mg/dl, 90 to <100 mg/dl, 100 to <110 mg/dl, 110 to <126 mg/dl, and diabetes, respectively. The crude mean WBC counts differed significantly by FPG category and showed a U-shaped association with FPG levels (*P* value for quadratic trend <0.001). Even after adjusting for age, BMI, smoking, alcohol, health status, and other factors associated with elevated WBC count or glycometabolism, the respective adjusted-mean WBC counts were 6,273, 6,255, 6,175, 6,165, 6,075, and 6,429 cells/mm³. The WBC count maintained a U-shaped association with FPG level (*P* value for quadratic trend = 0.041).

Although it is well known that hyperglycemia is the cause of microvascular complications in several organs, there are few studies on the adverse effect of hypoglycemia. Early studies of hypoglycemia focused on brain damage and heart dysfunction. An acute decrease in FPG is recognized as the cause of them, whereas the long-term effect of low FPG remains unclear.

Infection and inflammation may contribute to vascular injury and atherogenesis. Inflammation may also promote atherosclerotic plaque ruptures and thrombosis (2,3). WBC serves as an important biomarker for these disease processes.

This study shows that the U-shaped association between WBC counts and FPG levels (especially low FPG levels) involves higher WBC counts that could not be linked to inflammatory disease or other factors or to any disease known to increase WBC counts. These findings suggest that a state of low-grade systemic inflammation may be present not only in diabetic subjects but also in people with low FPG, possibly explaining in part the high risk of CVD and all-cause mortality of such people.

KOJI TAMAKOSHI, MD, PHD¹

HIROSHI YATSUYA, MD, PHD¹

TAKAAKI KONDO, MD, PHD¹

YOKO HORI, PHD¹

HUIMING ZHANG, MD¹

MIYUKI ISHIKAWA, ME¹

CHIYOE MURATA, MPH¹

REI OTSUKA, BSC¹

SHANKUAN ZHU, MD, PHD²

HIDEAKI TOYOSHIMA, MD, PHD¹

From the ¹Department of Public Health/Health Information Dynamics, Field of Social Life Science, Nagoya University Graduate School of Medicine, Nagoya, Japan; and the ²Obesity Research Center, St. Luke's/Roosevelt Hospital Center, Columbia University College of Physicians & Surgeons, New York, New York.

Address correspondence to Koji Tamakoshi, Department of Public Health/Health Information Dynamics, Field of Social Life Science, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: tamako@med.nagoya-u.ac.jp.

References

1. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN: Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. *Circulation* 101:2047–2052, 2000

2. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA: Leukocytes and the risk of ischemic diseases. *JAMA* 257: 2318–2324, 1987
3. Fuster V, Lewis A: Conner Memorial Lecture: Mechanisms leading to myocardial infarction: insights from studies of vascular biology. *Circulation* 90:2126–2146, 1994

Impact of an Intramural Competition on Outcome of Diabetes Care

The translation of research results in diabetes (1) to clinical practice continues to be a major challenge (2,3). Physicians in training present a unique opportunity for shaping practice behavior. We tested the effect of an intramural contest on the outcome of diabetes management by 155 medical residents at a major U.S. teaching hospital. The contest was approved by the house staff leadership and was set for a 6-month period (1 October to 30 April). The residents, organized into four firms (A, B, C, and D), used various strategies (e.g., didactic lectures, case-based learning, and journal reviews) during weekly firm meetings to enhance competitiveness.

The outcome measures were HbA_{1c} levels (primary) and testing frequency (secondary). These data, extracted from 100 randomly selected charts of diabetic patients from each firm, were compared during and 6 months before the contest. Data from patients who had two or more HbA_{1c} results during the contest were used for analysis of the primary outcome. The “baseline” HbA_{1c} was the first measured value during the contest, and the “final” HbA_{1c} was the last result obtained before conclusion of contest. For comparison, HbA_{1c} data obtained during the 6 months preceding the contest (“precontest”) were analyzed. Results are means ± SE. Statistical analyses were by paired *t* test for changes in HbA_{1c} values, and the χ^2 test was used for HbA_{1c} testing frequency. The prizes included a plaque and

- aker EJ, Defronzo R, Mandarino LJ, Kahn CR: Analysis of differential gene expression in skeletal muscle from subjects with insulin resistance and type 2 diabetes (Abstract). *Diabetes* 50 (Suppl. 2):A247, 2001
4. Stokov IA, Manukhina EB, Bakhtina LY, Malyshev IY, Zolov GK, Kazikhanova SI, Ametov AS: The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy. *Bull Exp Biol Med* 130:986–990, 2000
 5. Malyshev IY, Manukhina EB, Mikoyan VD, Kubrina LN, Vanin AF: Nitric oxide is involved in heat-induced HSP70 accumulation. *FEBS Lett* 370:159–62, 1995
 6. Suematsu Y, Ohtsuka T, Horimoto H, Maeda K, Nakai Y, Mieno S, Takamoto S: Long-term treatment with nipradilol, a nitric oxide-releasing beta-adrenergic blocker, enhances postischemic recovery and limits infarct size. *Ann Thorac Surg* 73:173–179, 2002
 7. Hattori Y, Nakanishi N, Kasai K: Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. *Cardiovasc Res* 54:649–658, 2002
 8. Angiotensin-converting: enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. *Circulation* 105:2785–2790, 2002
 9. Fujishima S, Ohya Y, Nakamura Y, Onaka U, Abe I, Fujishima M: Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. *Am J Hypertens* 11:1134–1137, 1998
 10. Roberts CK, Barnard RJ, Jasman A, Balon TW: Acute exercise increases nitric oxide synthase activity in skeletal muscle. *Am J Physiol* 277 (2 Pt 1):E390–E394, 1999
 11. Walsh RC, Koukoulas I, Garnham A, Moseley PL, Hargreaves M, Febbraio MA: Exercise increases serum Hsp72 in humans. *Cell Stress Chaperones* 6:386–393, 2001
 12. Vigh L, Literati PN, Horvath I, Torok Z, Balogh G, Glatz A, Kovacs E, Boros I, Ferdinandy P, Farkas B, Jaszlits L, Jednakovits A, Koranyi L, Maresca B: Bimocloamol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. *Nat Med* 3:1150–1154, 1997
 13. Kurthy M, Mogyrosi T, Nagy K, Kukorelli T, Jednakovits A, Talosi L, Biro K: Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. *Ann N Y Acad Sci* 967:482–489, 2002
 14. Hooper PL: Hot-tub therapy for type 2 diabetes mellitus. *N Engl J Med* 341:924–925, 1999

Heteroplasmic Mitochondrial DNA C3310 Mutation in NADH Dehydrogenase Subunit 1 Associated With Type 2 Diabetes, Hypertrophic Cardiomyopathy, and Mental Retardation in a Single Patient

The patient of this letter is a 57-year-old Japanese man with type 2 diabetes and mental retardation with maternal inheritance. The younger of his two sisters was healthy. An echocardiography and a myocardial biopsy revealed hypertrophic cardiomyopathy in the patient. Electron microscopic examination showed a marked increase of mitochondria and abnormal cristae in the myocardial fibers. Autopsy revealed both decrease and atrophy of pancreatic islets of Langerhans. Immunohistochemical staining showed a selective decrease of β -cells. Based on these findings, mitochondrial disease was suspected.

The mtDNA of the patient and his two sisters was studied by cloning and sequencing. Three unique point mutations were found in the patient's lymphocytes. Two point mutations (C11215T and A15874G) were silent. The other mutation was C3310T in the ND1 gene. Two clones of mtDNA without the C3310T point mutations were obtained from the patient's pancreas. However, all mtDNA extracted from the patient's other tissues and his sisters' lymphocytes had this mutation. None of the mtDNAs extracted from lymphocytes from 97 patients with type 2 diabetes and 82 normal control subjects that were evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP) had this mutation. Informed consent was obtained from all participants.

The ND-1 gene encodes the NADH dehydrogenase (complex I) subunit 1. The C3310T point mutation replaces the hydrophobic amino acid proline with the

hydrophilic serine. Other mutations in this region have been reported to be associated with diabetes (1,2) and Leber's hereditary optic neuropathy (3). All reported mtDNA point mutations in this region have been homoplasmic. It has been assumed that other unknown pathogenic mtDNA changes, nuclear DNA changes, or environmental factors are involved in disease causation (1).

We obtained two mtDNA samples without the mutation from the patient, suggesting that the C3310T point mutation is heteroplasmic and the single pathogenic gene. However, other samples, even from the healthy sister, had only mutant mtDNA. Therefore, other factors cannot be ruled out. Since this mutation was not detected by PCR-RFLP, it is likely to occur rarely.

YUKIKO HATTORI, MD¹
 KAZUO NAKAJIMA, MD¹
 TAKAYUKI EIZAWA, MD¹
 TAKASHI EHARA, MD²
 MASAMICHI KOYAMA, MD³
 TETSUYA HIRAI, PHD⁴
 YUJI FUKUDA, PHD⁴
 MORITOSHI KINOSHITA, PHD⁴

From the ¹Department of Internal Medicine, Asama General Hospital, Nagano, Japan; the ²Department of Pathology, Shinshu University School of Medicine, Nagano, Japan; the ³Department of Pathology, Komoro Kosei General Hospital, Nagano, Japan; and ⁴Gene Analysis Center, Otsuka Assay Laboratories, Otsuka Life Science Initiative, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan

Address correspondence to Yukiko Hattori, MD, Department of Molecular Oncology and Angiology, Research Center on Aging and Adaptation, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto City, Nagano, Japan, 390-8621. E-mail: u-chan@avis.ne.jp.

References

1. Nakagawa Y, Ikegami H, Yamato E, Takekawa K, Fujisawa T, Hamada Y, Ueda H, Uchigata Y, Miki T, Kumahara Y, Ogihara T: A new mitochondrial DNA mutation associated with non-insulin-dependent diabetes mellitus. *Biochem Biophys Res Commun* 209:664–668, 1995
2. Hirai M, Suzuki S, Onoda M, Hinokio Y, Ai L, Hirai A, Ohtomo M, Komatsu K, Kasuga S, Satoh Y, Akai H, Toyota T: Mitochondrial DNA 3394 mutation in the NADH dehydrogenase subunit 1 associated with non-insulin-dependent diabetes mellitus. *Biochem Biophys Res Commun* 219:951–955, 1996
3. Majander A, Huoponen K, Savontaus ML, Nikoskelainen E, Wikstrom M: Electron

transfer properties of NADH: ubiquinone reductase in the ND1/3460 and the ND4/11778 mutations of the Leber hereditary optic neuroretinopathy (LHON). *FEBS Lett* 292:289–292, 1991

A New Case Of Lipoatrophy With Lispro Insulin In Insulin Pump Therapy

Is there any insulin preparation free of complications?

Lipoatrophy as a cutaneous complication of insulin therapy has been extremely rare since the introduction of recombinant human insulin. Lispro insulin was not reported to be associated with this complication, but recently, Griffin et al. (1) published the first two cases

of lipoatrophy associated with lispro insulin in two insulin pump-treated patients. We observed a singular case in which lipoatrophy occurred in two different locations with both buffered human regular insulin and lispro insulin in a patient treated by continuous subcutaneous insulin infusion (CSII).

We studied a 29-year-old Caucasian woman diagnosed with type 1 diabetes at 23 years of age. She began intensified insulin therapy with two premixed insulin injections before breakfast and dinner and regular insulin before lunch (22 units/day, 64% NPH insulin). She developed a primary hypothyroidism 1 year later and started treatment with sodium levothyroxine. She was transferred to our hospital in 1998. In the following 2 years, several combinations of NPH and regular insulin were used to reduce hypoglycemia, but optimized blood glucose was not achieved.

She began CSII (MiniMed 507 C; Soft-set Micro) with human regular insulin (Actrapid; NovoNordisk) in December 1999. Under CSII, HbA_{1c} improved to

6.6–6.8% and the number of hypoglycemic episodes were reduced. Seven months after initiation of CSII, lipoatrophy was noted in the subcutaneous tissue of the anterior abdominal wall (Fig. 1A), although frequent change of catheter site every 3 days was performed. Initially, she was prompted to avoid the abdominal area for catheter insertion, but therapy was continued with buffered human regular insulin.

Treatment was also changed from buffered regular human insulin to lispro insulin 10 months later, due to deterioration of metabolic control. Eleven months after the initiation of lispro and using another 6-mm Teflon catheter (Quick-set), she noticed a new area of lipoatrophy on the right buttock, but it was of lesser extension (Fig. 1B). Both areas of lipoatrophy persisted until the date of submission for this article, and no further progression of skin lesions has been seen.

This case confirms a previous observation that lispro insulin might also induce lipoatrophy (1). Interestingly, lipoatrophy in our patient was associated




Figure 1—Lipoatrophic area due to human regular insulin (A) and to lispro insulin (B).

with both lispro and recombinant human insulin. Although the lispro-induced lipoatrophic area was smaller, this case pointed out that local factors related to CSII use might play also a role. Nowadays, teflon catheters are the most common infusion sets used by pump-treated patients. They are placed by means of specially-designed devices. Although teflon cannulae are soft and comfortable, they could also induce local changes that lead to lipoatrophy in susceptible patients.

It has been previously suggested that lipoatrophy results from a local immune reaction to insulin crystals (2). The inflammatory response includes local hyperproduction of tumor necrosis factor- α from macrophages that led to differentiation of adipocytes (lipoblastoma-like lipoatrophy) (2). Because lispro and recombinant human insulin had similar immunogenicity (3), the exact role of insulin autoantibodies is unclear. The reason that the lispro-induced lipoatrophic area in our patient was smaller may be related to the reduced ability of lispro insulin to aggregate.

F. JAVIER AMPUDIA-BLASCO, MD
BENHARD HASBUM, MD
RAFAEL CARMENA, MD

From the Diabetes Reference Unit, Endocrinology Department, Valencia Clinic University Hospital, Valencia, Spain.

Address correspondence to F. Javier Ampudia-Blasco, Diabetes Reference Unit, Endocrinology Department, Valencia Clinic University Hospital, Avda. Blasco Ibáñez, 17, E-46010 Valencia, Spain. E-mail: francisco.j.ampudia@uv.es.

References

1. Griffin ME, Feder A, Tamborlane WV: Lipoatrophy associated with lispro in insulin pump therapy (Letter). *Diabetes Care* 24:174, 2001
2. Jermendy G, Nádas J, Sápi Z: "Lipoblastoma-like" lipoatrophy induced by human insulin: morphological evidence for local dedifferentiation of adipocytes? *Diabetologia* 43:955-956, 2000
3. Fineberg NS, Fineberg SG, Anderson JH, Birkett MA, Gibson RG, Hufferd S: Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. *Diabetes* 45:1750-1754, 1996

Intensive Insulin Treatment and QT-interval

Rate-corrected QT-interval (QT_c) and QT-dispersion (QT_{disp}) are two related electrocardiographic variables that, apart from assessing the autonomic dysfunction, can also predict cardiac death in diabetic patients. Several studies have suggested that change of QT_{disp} reflects the "dynamic pathological process" in a variety of cardiac diseases. Particularly, QT_{disp} was found to increase significantly during ischemia and to decrease after anti-ischemic treatment during acute coronary syndromes (ACS) (1).

The beneficial effect of optimal metabolic control achieved by intensive insulin therapy on the outcome of diabetic patients suffering from acute myocardial infarction has already been reported (2). Nevertheless, hyperinsulinemia has also been reported to increase QT_c and QT_{disp} in healthy subjects (3). The potential effect of intensive insulin administration during ACS on the electrocardiographic ventricular repolarization variables remains to be elucidated.

We studied 66 non-insulin-treated type 2 diabetic patients with ACS without ST-segment elevation and no previous myocardial infarction. A total of 31 patients were randomized to receive conventional anti-ischemic therapy plus intensive insulin treatment (group A), and 35 received conventional therapy only (group B). Group A patients received soluble insulin by infusion for 72 h according to a predefined protocol aiming to maintain near-normal glycemia (4). Group B patients were treated according to coronary care unit usual care, with oral hypoglycemic drugs or two daily doses of intermediate-acting insulin.

QT-interval variables were determined on two occasions: admission and 72 h later. A single investigator with no knowledge of the clinical data interpreted QT-intervals manually. QT-values were corrected for heart rate using Bazett's formula ($QT_c = QT/RR^{-1}$). QT_{disp} was calculated as the difference between the longest and shortest measured QT-interval. Informed consent was obtained from all patients.

The two groups were comparable according to baseline clinical and investiga-

tive characteristics. In group A, glucose values were maintained within near normoglycemic range during the study period (group A versus B: 7.1 ± 1.6 vs. 10.9 ± 2.7 mmol/l $^{-1}$, $P < 0.001$). At 72 h, QT_{disp} decreased significantly only in group A patients (QT_{disp} 72 h: 46 ± 24 vs. 58 ± 19 m/s, $P < 0.05$), supporting the hypothesis that a more homogeneous electrical recovery state of myocardium was achieved by optimal glycemic control. Conversely, QT_c showed a trend to increased values in intensively treated patients (QT_c 72 h: 429 ± 37 vs. 409 ± 45 m/s, $P = 0.072$). This observation was rather disappointing, since QT_c prolongation is another key factor that predisposes to cardiac arrhythmias, especially in ischemic conditions. Importantly, the change in potassium was not correlated to the degree of QT prolongation.

Our findings stress that the impact of intensive insulin treatment on repolarization of the diabetic heart during ACS is rather controversial. One may remember the phrase of Hippocrates in one of his writings 25 centuries ago, "As to diseases, make a habit of two things—to help, or at least to do no harm" (5).

STEFANOS FOUSSAS, PHD
ALEXANDER STEFANIDIS, MD
ANDREAS MELIDONIS, PHD
SYMEON TOURNIS, MD
PANAYIOTIS MICHAEL, PHD
THEODOSIOS DOSIOS, PHD
PANAYIOTIS ASIMACOPOULOS, PHD

From the Cardiology Department, Tzanio Hospital, Piraeus, Greece.

Address correspondence to Alexander Stefanidis, Cardiology Department, Tzanio Hospital, 1 Afentouli and Zanni str, PC: 185-36, Piraeus, Greece. E-mail: plato203@compulink.gr.

References

1. Malik M, Batchvarov V: Measurement, interpretation and clinical potential of QT dispersion. *J Am Coll Cardiol* 36:1749-1766, 2000
2. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. *BMJ* 314:1512-1515, 1997
3. Watanabe T, Ashikaga T, Nishizaki M, Yamawake N, Arita M: Association of insulin with QT_c dispersion. *Lancet* 350:

the overweight, and 48 in the obese). The frequencies of Trp/Trp, Trp/Arg, and Arg/Arg were 82.1%, 17.0%, and 0.9% in the nonobese group, 61.9%, 33.3%, and 4.8% in the overweight group, and 64.6%, 33.3%, and 2.1% in the obese group, respectively. The allele frequencies of the Arg64 in the nonobese, the overweight, and the obese groups were 9.4%, 21.4%, and 18.8%, respectively. The genotype frequencies of Trp/Arg and the mutant allele frequencies were significantly higher in the overweight and the obese subjects than in the nonobese subjects. There was no significant difference between the overweight subjects and the obese subjects.

Since it has been reported that the Pro12Ala substitution in PPAR γ 2 is associated with lower BMI, improved insulin sensitivity, and lower prevalence of type 2 diabetes (7), the Pro12Ala polymorphism in PPAR γ 2 is considered to have a preventive effect against the development of obesity and type 2 diabetes. The absence of the Pro12Ala substitution in PNG people had suggested that people in PNG have susceptibility to obesity and type 2 diabetes. In addition, the frequency of Trp64Arg polymorphism in the β 3-AR in PNG subjects was significantly higher in the overweight and obese subjects than in the nonobese subjects. Thus, the Trp64Arg polymorphism in the β 3-AR seems to be one of major genetic factors related to obesity in subjects of PNG.

As genes we had analyzed in the present study are considered to be thrifty genes, people in PNG are thought to have thrifty genotype. Austronesian-speaking people in PNG have been reported to share the same genotype with Polynesians. Therefore, it is expected that the prevalence of obesity and type 2 diabetes will increase at least to the same extent as currently seen in Polynesians with westernization of their lifestyle (8).

Acknowledgments—This work is partly supported by a grant-in-aid for Scientific Research (B) from the Japan Society for the Promotion of Science (no. 12576021).

MOTOYOSHI SAKAUE, MD, PHD^{1,2}
 YOKO FUKU, BS³
 TOSHIE KATSUYAMA, BS³
 MASATO KAWABATA, MD⁴
 HIROSHI TANIGUCHI, MD, PHD³

From the ¹Division of Diabetes, Digestive and Kidney Diseases, Department of Clinical Molecular

Medicine, Faculty of Medical Science, Kobe University Graduate School of Medicine, Kobe, Japan; the ²School of Humanities for Environmental Policy and Technology, Himeji Institute of Technology, Himeji, Japan; the ³Department of Metabolism and Community Health Science, Faculty of Health Science, Kobe University Graduate School of Medicine, Kobe, Japan; and the ⁴International Center for Medical Research, Faculty of Medical Science, Kobe University Graduate School of Medicine, Kobe, Japan.

Address correspondence to Dr. Motoyoshi Sakaue, Division of Diabetes, Digestive and Kidney Diseases, Department of Clinical Molecular Medicine, Faculty of Medical Science, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. E-mail: sakaue@med.kobe-u.ac.jp.

References

- Price AV, Tulloch JA: Diabetes mellitus in Papua and New Guinea. *Med J Aust* 2: 645–648, 1966
- Martin FI, Wyatt GB, Griew AR, Haurahe- lia M, Higginbotham L: Diabetes mellitus in urban and rural communities in Papua New Guinea: studies of prevalence and plasma insulin. *Diabetologia* 18:369–374, 1980
- Dowse GK, Spark RA, Mavo B, Hodge AM, Erasmus RT, Gwalimu M, Knight LT, Koki G, Zimmet PZ: Extraordinary prevalence of non-insulin-dependent diabetes mellitus and bimodal plasma glucose distribution in the Wanigela people of Papua New Guinea. *Med J Aust* 160:767–774, 1994
- Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Haagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T: The Pro12Ala polymorphism in PPAR γ 2 may confer resistance to type 2 diabetes. *Biochem Biophys Res Commun* 271:212–216, 2000
- Widen E, Lehto M, Kanninen T, Waltson J, Shuldiner AR, Groop LC: Association of a polymorphism in the β 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. *N Engl J Med* 333:348–351, 1995
- Fukuda Y, Inaoka T, Futatsuka M, Kawabata M, Akita Y, Ohtsuka R: Serological survey for viral infections in Austronesian-speaking Balopa Islanders, Papua New Guinea. *Kumamoto Med J* 46:47–54, 1999
- Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPAR γ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat Genet* 20:284–287, 1998
- Papoz L, Barny S, Simon D: Prevalence of diabetes mellitus in New Caledonia: ethnic and urban-rural differences. CALDIA Study Group. CALedonia DIAbetes Mel-

litus Study. *Am J Epidemiol* 143:1018–1024, 1996

Metformin-Induced Hemolytic Anemia in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency

Metformin-induced hemolytic anemia has been reported only twice. Here we describe another case of hemolysis associated with the initiation of metformin therapy.

A 68-year-old married woman of North-African Jewish descent was admitted to our internal medicine department due to newly diagnosed diabetes, with weakness, presyncope, and blood glucose levels as high as 500 mg/dl. There was no acidosis, HbA_{1c} was 14%, and C-peptide was below normal. A low-sugar diet was started, together with metformin 850 mg t.i.d. and repaglinide 1 mg t.i.d., in addition to ramipril 1.25 mg daily because of albuminuria and elevated blood pressure. On the seventh hospital day the patient was discharged euglycemic, in stable condition.

A week later she presented to the emergency room with extreme weakness, and anemia was noted, which was not present on previous laboratory examinations. The hemoglobin was 8 g/dl, having fallen from 12 g/dl the previous week. No history or signs of gastrointestinal bleeding were found, and stools for occult blood were negative. Mild jaundice was noted; otherwise the physical examination was unremarkable. Mean corpuscular volume was 96 fl, and the reticulocyte count was 11%, with marked polychromasia on peripheral smear. The serum iron, transferrin, serum levels of vitamin B12, and folic acid were normal, and ferritin was high. Serum bilirubin rose to 35 mmol/l, most of it (27 mmol/l) indirect; plasma lactate dehydrogenase concentration was at the upper limit of normal; plasma haptoglobin concentration was low; and the direct Coombs test was negative. The abdominal ultrasound was normal.

No Delay in Glucose Change at Antecubital Skin in Hypoglycemia of Normal Subjects

In the July 2001 issue of *Diabetes Care*, Jungheim and Koschinsky (1) reported that capillary blood glucose values at forearm lagged behind those at fingertip by maximum 30 min in their particular type 1 diabetic patient rendered to hypoglycemia. They warned that this might result in delay of hypoglycemia detection in diabetic patients and endangered their lives. They hypothesized that this was a physiological phenomenon rather than a pathological delay.

We investigated if their observation was physiological. We had 10 nondiabetic healthy volunteers (8 males and 2 females aged 35.0 ± 11.2 years with a BMI of 22.2 ± 3.0 kg/m²) who were hypoglycemic with intravenous bolus injection of human insulin 0.1 unit/kg body

Metformin was discontinued, and treatment with ramipril and repaglinide was continued. After transfusion of two units of erythrocytes, the hemoglobin rose to 11 g/l and remained stable (>2 months of follow-up). One month after discharge, red cell glucose-6-phosphate dehydrogenase (G6PD) activity was found significantly decreased.

Metformin-induced hemolysis seems to be a very rare complication of therapy, as this is only the third case reported in the literature (1,2). In all three cases, hemolysis appeared during the first 12 days of therapy; only in one case was the Coombs test positive (2), and the G6PD activity was normal in both previous cases.

This is the first case in which G6PD activity was found significantly decreased. It is possible that in our patient, metformin caused G6PD-mediated hemolysis or the hemolysis induced by metformin was not related to the presence of the G6PD deficiency. There was no precipitating event (fever, other drug use), which would have caused hemolysis due to the G6PD deficiency.

Although hemolytic anemia is a rare adverse effect of metformin, the physician and pharmacist should be aware of this potentially serious side effect of the drug, particularly in a patient with G6PD deficiency.

ANTOPOLSKY MEIR, MD¹
 YOSEF KLEINMAN, MD¹
 DEBORAH RUND, MD²
 NAEL DA'AS, MD¹

From the ¹Department of Internal Medicine, Bikur Cholim Hospital, Jerusalem, Israel; and the ²Department of Hematology, Hadassah University Hospital, Jerusalem, Israel.

Address correspondence to Nael Da'as, MD, Department of Internal Medicine, Bikur Cholim Hospital, PO Box 492, Jerusalem 91004, Israel. E-mail: daasn@surfnet.net.il.

.....

References

1. Lin KD, Lin JD, Juang JH: Metformin induced hemolysis. *N Engl J Med* 339: 1860-1861, 1998
2. Kashyap AS, Kashyap S: Haemolytic anaemia due to metformin. *Postgrad Med J* 76: 125-126, 2000




Figure 1—Insulin-induced hypoglycemia in healthy subjects. Glucose levels are monitored at three sites of the forearm: fingertip (■), antecubital skin (▲), and antecubital vein (◆). Only average values are given. Bolus injection of human insulin is given at time 0. No significant differences are observed between glucose levels of fingertip and antecubital skin at any time in this study. Glucose levels in antecubital vein are significantly lower than those of the other two sites at the time marked by * or #. *P < 0.01, #P < 0.05.

wt. Blood glucose levels were monitored at three different unilateral forearm sites: antecubital vein, capillary blood from antecubital skin, and fingertip. Three blood samples were taken strictly simultaneously with 5–10 min intervals for 90 min at three sites with venipuncture or pricking by three laboratory technicians. All blood samples from antecubital skin were taken after rubbing the skin. These samples were analyzed instantly for glucose by Free Style glucometers (Nipro, Osaka, Japan), which requires only 0.3 μ l of whole blood for determination.

As described in Fig. 1, we found two major differences with Jungheim and Koschinsky's findings: 1) we observed no significant difference in blood glucose levels between those from antecubital capillary blood and fingertip; and 2) we noticed no delay in blood glucose nadirs among the three monitored sites. Changes at all sites were entirely concomitant. We see no advantage of measuring fingertip glucose over antecubital capillary blood glucose for these two reasons. Different from other two sites, antecubital venous blood glucose values were always significantly lower ($P < 0.01$ – 0.05) than those levels of either antecubital or fingertip from -20 to 45 min throughout. Therefore, if we want to detect hypoglycemia as early as possible, then we have to monitor venous blood glucose rather than either antecubital or fingertip. We do not think this is feasible and practical for the patients.

Blood glucose changes in hypoglycemia at antecubital and fingertip proceed synchronously without any delay in normal subjects (Fig. 1). We observed no delay in blood glucose changes in capillary blood at forearm as described by Jungheim and Koschinsky on their type 1 diabetic patient. They hypothesized that this could be a physiological delay, which is not consistent with our findings. Since diabetes is a disease of vascular complications and of autonomic neuropathy, one cannot rule out possible vascular reorganization or vascular nerve dysfunction after decades of hyperglycemia, leading to a possible delay in some cases of forearm glucose level detection than in fingertip. Their observation in type 1 diabetes, however, cannot be generalized as physiological; rather, it may represent an inconsistent and pathological finding observed in a limited range of patients. We need further investigation of diabetic

patients with a variety of vascular or neural complications caused by various length or severity of diabetes to obtain a definite conclusion.

KYOHEI NONAKA, MD, PHD
FUKIMI ONO, CDE
MIYUKI ISHIBASHI, CDE
NOBUMITSU OKITA, MD, PHD

From the Department of Medicine, Shiroishi Kyoritsu Hospital, Saga Prefecture, Japan.

Address correspondence to Kyohei Nonaka, Department of Medicine, Shiroishi Kyoritsu Hospital, 1296 Fukuda, Shiroishi-Cho, Saga Prefecture, Japan 849-1112. E-mail: seibindo@po.saganet.ne.jp.

.....

References

1. Jungheim K, Koschinsky T: Risky delay of hypoglycemia detection by glucose monitoring at the arm (Letter). *Diabetes Care* 24:1303–1304, 2001

Pregnancy Complicated by Diabetic Ketoacidosis

Maternal and fetal outcomes

Despite intensified insulin treatment and strict surveillance of metabolic control in diabetic women during pregnancy, diabetic ketoacidosis (DKA) complicates 2–9% of diabetic pregnancies (1) and represents the leading cause of fetal loss, with a fetal mortality rate of 30–90% (1–3).

From August 1991 to December 2001, 2,025 pregnant women with diabetes were admitted to the University of Tennessee Women's Hospital. Of these, 888 women (44%) received insulin therapy, and 11 women (1.2%) presented with DKA (blood glucose: 377 ± 27 mg/dl, pH: 7.22 ± 0.01 , bicarbonate 7.9 ± 3 mEq/l, and positive serum ketones). White's diabetic classification included class A₂, four patients (27%); class B, five patients (45%); class C, one patient (9%); and class D, one patient (9%). The four women with gestational diabetes mellitus (GDM) were African-American, had a mean age of 25 ± 1 year, a BMI of 34 ± 3 kg/m², and an estimated gestational age of 29 ± 1 weeks. Patients with a previous history of diabetes had a mean duration of

diabetes of 6 ± 1 year, a mean age of 27 ± 1 year, a BMI of 30 ± 2 kg/m², and a gestational age of 28 ± 1 weeks.

Infection (27%) and a history of the omission of insulin therapy (18%) were the most common precipitating causes. There were no maternal deaths, and the mean maternal length of hospital stay was 7 ± 2 days. Two patients presented with intrauterine fetal demise, and there was one additional fetal death giving an overall fetal death rate of 27%. During labor, four patients had nonreassuring fetal heart rate tracings in the form of late decelerations that resolved with correction of DKA. At birth, the mean (5 min) Apgar was 8.7 ± 0.4 , and fetal weight was $1,278 \pm 202$ g.

Four obese women with DKA had newly diagnosed diabetes; one of them presented with an intrauterine fetal demise, and the remaining three reached full-term pregnancy. Insulin therapy was discontinued in all four patients after delivery; and two women remained off insulin after 6 months and 6 years of follow-up. GDM presenting with DKA is unusual (3). Our study indicates that DKA could be the clinical presentation of GDM and that many of these women can discontinue insulin treatment shortly after delivery. The four women with GDM and DKA were obese African-Americans resembling the phenotypic characteristics of patients with atypical diabetes (4).

In conclusion, DKA remains an important cause of fetal loss in diabetic pregnancies. Strict surveillance of glucose homeostasis and aggressive management might reduce the high perinatal mortality associated with DKA.

MICHAEL B. SCHNEIDER, MD¹
GUILLERMO E. UMPIERREZ, MD^{1,2}
RISA D. RAMSEY, PHD¹
WILLIAM C. MABIE, MD¹
KELLY A. BENNETT, MD¹

From the ¹Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee; and the ²Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.

Address correspondence Guillermo Umpierrez, MD, Associate Professor of Medicine, Obstetrics and Gynecology, University of Tennessee Health Science Center, 951 Court Ave., Room 335M, Memphis, TN 38163. E-mail: gumpierrez@utm.edu.

96.9 ± 13.1 mm², as compared with 3.61 ± 1.6 mm² after 10 weeks. The observed weekly wound radius reduction was 0.39 mm (95% CI 0.32–0.48) with an observed average healing time of 75.9 (95% CI 71–81) days, which was slightly less than the predicted healing time of 86.9 (95% CI 73–101) days. The observed and predicted healing times were significantly correlated with each other ($r = 0.55$, $P = 0.0002$). Both the wound area and the wound radius at study entry were significantly correlated with the healing times (area: $r = 0.94$, $P = 0.005$; radius: $r = 0.99$, $P = 0.0001$). The wound area reduction follows a second degree exponential function, with most of the wound area reduction taking place within the first weeks of treatment.

The results of this study confirm that the healing time in neuropathic foot ulcers can reliably be predicted by using the equation $R = \sqrt{A/\pi}/0.45$. Such calculations may be regarded as a useful tool in daily clinical practice, both to give an estimation of the time period needed for healing, and to recognize early those ulcers that do not respond adequately to the treatment.

STEFAN ZIMNY, MD
ANDREAS VOIGT, MD
HELMUT SCHATZ, MD
MARTIN PFOHL, MD

From BG-Kliniken Bergmannsheil Bochum, Internal Medicine, Bochum, Germany.

Address correspondence to Stefan Zimny, BG-Kliniken Bergmannsheil Bochum, Clinic of Internal Medicine, Buerkle-de-la Camp Platz 1 D-44789 Bochum, Germany. E-mail: stefan.zimny@ruhr-uni-bochum.de.

References

- Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG, Harkless LB, Boulton AJM: The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. *Diabet Med* 18:133–138, 2001
- Zimny S, Schatz H, Pfohl M: Determinants and estimation of healing duration in diabetic foot ulcers. *J Diabet Complic* 16:327–332, 2002
- Mayrovitz HN, Smith J, Ingram C: Geometric, shape and area measurement considerations for diabetic neuropathic plantar ulcers. *Ostomy Wound Manage* 43: 58–55, 1997

Evidence for Associated Cutaneous Microangiopathy in Diabetic Patients With Neuropathic Foot Ulceration

Diabetes complicated by diabetic neuropathy is a risk factor initiating chronic foot ulceration, which may lead to amputation (1).

We postulated that a form of functional cutaneous microangiopathy is associated with diabetic neuropathy, and we assessed the cutaneous vasoreactivity reserve (CVR) using laser-Doppler flowmetry.

We investigated 42 patients with type 2 diabetes but without cutaneous foot ischemia. They were divided into two groups, respectively comprising 30 patients with no current or previous foot ulceration and 12 with diabetic neuropathy and foot ulceration. A total of 17 healthy subjects served as the control group.

A laser-Doppler probe was placed on the dorsum of the foot. Blood flux was recorded as previously published (2), under three conditions: supine, sitting (to record the venous arteriolar reflex [VAR]), and after postocclusive hyperemia (H). CVR is the sum of these vasoconstriction (VAR) and vasodilation (H) capacities and is expressed in percent of the supine blood flux. In addition, we measured the transcutaneous oxygen pressure (TcPO₂) of the foot dorsum.

In diabetic patients with foot ulceration, CVR was 219 ± 86%, which was significantly lower than in either the group without foot ulceration (566 ± 76%, $P < 0.01$) or the healthy control subjects (472 ± 217%, $P < 0.017$).

In diabetic patients with foot ulceration, TcPO₂ was 44.5 ± 5 mmHg, which was also lower than in either the group without foot ulceration (50 ± 1 mmHg, $P = NS$) or the healthy control subjects (68 ± 8 mmHg, $P = 0.0005$).

In diabetic patients with neuropathy complicated by foot ulceration, this study demonstrated a significant reduction in CVR, indicating the presence of cutaneous microangiopathy.

Our study is the first to have explored

both VAR and H simultaneously, thus enabling them to be summed in a single parameter (CVR) that expresses the cutaneous vasoreactivity reserve.

The relationship between neuropathy and cutaneous microangiopathy might involve two mechanisms: 1) the impairment of microvascular reactivity and limitation of hyperemia by the neuropathy 2) disturbance of the vasa nervorum and interference in the pathogenesis of the neuropathy.

Note that the functional microcirculatory abnormalities shown by our results had nutritional consequences for the blood oxygen supply to the skin, as TcPO₂ was lower in patients with diabetes than in the control subjects, the lowest values being in the group with foot ulceration.

The cutaneous microvascular vasodilation capacity (i.e., hyperemia in response to injury) is of particular importance for ulcer healing, and the capillary hyperperfusion on dependency due to an abnormal postural venoarteriolar reflex accounts for edema and stimulates capillary basement membrane thickening. Therefore, the traditional causative chain of neuropathy + minor trauma → ulceration + faulty healing → gangrene → amputation does not take into account the associated cutaneous microangiopathy that may be expected to increase the proneness to trauma and foot ulceration and, hence, the possible failure of healing.

NATHALIE CHABBERT-BUFFET, MD^{1,2}
CLAUDE LEDEVEHAT, MD^{3,4}
TARANEH KHODABANDHELOU, PHD⁴
ERIC ALLAIRE, MD⁵
JEAN PIERRE GAITZ, MD¹
LAURENT TRIBOUT, MD¹
NATHALIE ABDOUCHELI-BAUDOT, MD¹
MICHEL VAYSSAIRAT, MD¹

From the ¹Unit of Vascular Medicine, Hôpital Tenon, Paris, France; the ²Department of Internal Medicine, Hôpital Tenon, Paris, France; the ³Department of Diabetology, Centre Hospitalier, Nevers, France; the ⁴Unit of Hemorrhological Research, Centre Hospitalier, Nevers, France; and the ⁵Department of Vascular Surgery, Hôpital Tenon, Paris, France.

Address correspondence to M. Vayssairat, Hôpital Tenon, 4 Rue de la Chine, 75020 Paris, France. E-mail michel.vayssairat@tnn.ap-hop-paris.fr.

References

- Young MJ, Breddy JL, Veves A, Boulton AJM: The prediction of diabetic neuropathic foot ulceration using vibration per-

- ception thresholds. *Diabetes Care* 17: 557–560, 1994
2. Tharaux PL, Girot R, Kanfer A, Dussaule C, Gaitz JP, Tribout L, Baudot N, Vays-sairat M: Cutaneous microvascular blood flow and reactivity in patients with homozygous cell anaemia. *Eur J Haematol* 68:327–331, 2002

COMMENTS AND RESPONSES

Coronary Artery Disease and Carotid Artery Intima-Media Thickness in Japanese Type 2 Diabetic Patients

We read with interest the article by Mitsuhashi et al. (1) concerning the role of carotid artery intima-media thickness (IMT) measurements in the detection of coronary artery disease (CAD) in Japanese type 2 diabetic patients. The article suggested that carotid IMT was significantly greater in diabetic patients with CAD (1.27 ± 0.07 mm) than in those without CAD (termed “control subjects”) (1.03 ± 0.04 mm, $P < 0.05$). In the subgroup with CAD, IMT was significantly greater in those who had undergone coronary artery bypass grafting (CABG) than in the non-CABG group (1.47 ± 0.11 vs. 1.07 ± 0.07 mm, $P < 0.05$). Although statistical differences in IMT between the CABG and non-CABG subgroups of CAD patients and between control subjects and the total CAD group were emphasized, no test statistic was given for the comparison of control subjects with non-CABG subjects, where the difference would appear to be nonsignificant (1.03 ± 0.04 vs. 1.07 ± 0.07 mm).

We question the validity of the authors' conclusions that early atherosclerosis in the carotid artery suggests a high probability of coronary involvement in Japanese patients with type 2 diabetes, and that an increased IMT in diabetic patients should prompt further screening for CAD to prevent progression of CAD.

First, there is the issue of possible confounding by the CABG procedure it-

self, which the authors do concede in their conclusion. Second, there is no evidence of a gradient of IMT between the CAD non-CABG group and those post-CABG, nor is there any correlation with number of vessels involved or any mention of correlation with severity of exercise electrocardiogram (ECG) results. It appears that the authors have demonstrated that in post-CABG patients, the IMT measurement offers the self-evident conclusion that they have CAD. A clinically relevant marker that can predict progression and perhaps be used as a screening tool, not one that merely confirms a clinically manifest condition, is needed.

This study has shown a statistical difference in serum HDL concentration, uric acid, and hypertension between the control and CAD groups, which is consistent with other large studies such as the Framingham Heart Study and the Multiple Risk Factor Intervention Trial (2–4), but no statistical difference between the non-CABG and post-CABG groups. Furthermore, only 32 of 48 subjects with abnormal exercise ECG testing proceeded to angiography. One wonders whether exclusion of 25% of subjects apparently eligible for angiography in this group may have led to an underestimation of the efficacy of IMT.

Finally, the abstract states that “carotid IMT was significantly greater in the diabetic patients than in the control subjects,” which implies that the control subjects were not diabetic. This is later clarified in RESEARCH DESIGN AND METHODS, which states that the control subjects were “drawn from the diabetic patients.”

Our conclusion is that, while this study has undoubtedly shown a statistical difference in IMT between type 2 diabetic patients with and without CABG, an increased IMT was only shown in those who had already undergone treatment for CAD. Therefore, it has not shown IMT to be a good marker to prompt further screening for CAD or treatment to prevent progression of CAD in type 2 diabetic patients.

JULIA E. OSTBERG, BSC, MRCP
STEVEN J. HUREL, PHD, FRCP

From the Department of Diabetes and Endocrinology, University College London Hospitals (UCLH), London, England, U.K.

Address correspondence to Steven J. Hurel, PHD, FRCP, Department of Diabetes and Endocrinology,

UCLH, Cleveland Street, London, England W1T 3AA, U.K. E-mail: s.hurel@ucl.ac.uk.

References

1. Mitsuhashi N, Onuma T, Kubo S, Takayanagi N, Honda M, Kawamori R: Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients. *Diabetes Care* 25:1308–1312, 2002
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 16:434–444, 1993
3. Kannel WB: Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. *Am Heart J* 110:1100–1107, 1985
4. Wilson PW, Castelli WP, Kannel WB: Coronary risk prediction in adults (the Framingham Heart Study). *Am J Cardiol* 59:91G–94G, 1987

Response to Ostberg and Hurel

We appreciate the interest of Ostberg and Hurel (1) in our article (2) and the opportunity to clarify the point raised.

As we described in CONCLUSIONS in our article, intima-media thickness (IMT) may have become thicker after coronary artery bypass grafting (CABG), because one cannot establish temporal sequence with cross-sectional data. We measured IMT of 15 patients before the CABG procedure (mean IMT \pm SD 1.44 ± 0.14 mm) and IMT of 5 patients within 3–6 months after CABG (1.56 ± 0.07 mm). IMT was not significantly different between these two groups ($P = 0.62$). Even if we had excluded the latter 5 patients' measured IMT after CABG, IMT would have been still significantly greater in the 15 CABG patients' measured IMT before CABG than in the controls drawn from the diabetic patients (1.44 ± 0.14 vs. 1.07 ± 0.07 mm, $P < 0.05$). And there is no conclusive proof that CABG itself has an effect on the change in IMT. Therefore, we did not consider that our result was confounded strongly by the CABG procedure itself. Yet, we need further studies, because the number of patients with CABG was relatively small, and we did

not compare IMT before and after CABG among the same patients.

Next, we state the correlation with the number of involved coronary vessels between two groups with and without CABG. The non-CABG group ($n = 20$) was divided into 9 patients with two-vessel disease and 11 patients with three-vessel disease. The CABG group ($n = 20$) included 4 patients with two-vessel disease and 16 patients with three-vessel disease. The CABG group had more severe disease than the non-CABG group, but the correlation was not significantly different ($\chi^2 = 2.849$, $P = 0.09$). In addition, we show the correlation between the severity of coronary artery disease (CAD) and IMT. In the group with two-vessel disease, the IMT was 1.08 ± 0.08 mm, and in the group with three-vessel disease, it was 1.36 ± 0.10 mm ($P = 0.07$). IMT was not significantly associated with the number of involved vessels, but had a tendency to associate with the number of total vessels. Moreover, as shown in Tables 2 and 3, IMT was independently associated with CAD by logistic regression analysis using all other independent variables. Thus, we consider that IMT could be used as a predictor of severity of CAD assessed by the number of involved vessels in diabetic patients.

With regard to the clinical characteristics, as shown in RESULTS, CAD patients had a significantly higher prevalence of hypertension and uric acid level and a lower HDL cholesterol level than the control diabetic patients. Both the Framingham Study (3,4) and Multiple Risk Factor Intervention Trial (MRFIT) (5), as referred to by Drs. Ostberg and Hurel, are studies to assess CAD mortality with and without diabetes, but the subjects of our study are all diabetic patients. Thus, we cannot compare these large studies with our study in the same way. Yet, it is well known that hyperlipidemia and hypertension are strong and independent predictors of CAD in diabetic patients (5–10). Similarly, our patients with CAD had more cardiovascular risk factors than those without CAD. On one hand, among only CAD patients, including the patients with and without CABG, as shown in Table 4, factors such as hypertension, hyperlipidemia, and hyperuricemia did not differ between the two groups. The reason was not obvious. But, as many of the patients without CABG already had hypertension and hyperlipidemia, there might

not have been a significant difference between the two groups with and without CABG. However, the IMT was significantly greater in patients with CABG than in those without CABG. These results indicate that IMT is one important indicator of severe CAD that was needed for CABG.

Currently, only 32 of 48 patients with abnormal exercise electrocardiogram testing proceeded to angiography. Some patients received an angiography after the period, but we estimated only 32 patients who had CAD by angiography from February 1998 to January 1999. Furthermore, we agree with Drs. Ostberg and Hurel that we should also state that the control subjects were drawn from the diabetic patients within RESULTS as well as within RESEARCH DESIGN AND METHODS. To clarify the meanings, the sentence in RESULTS should be replaced as follows: Carotid IMT was significantly greater in the CAD patients than in the controls drawn from the diabetic patients.

We believe that IMT is a predictor of severity of CAD in diabetic patients, but further investigation in a large population is necessary.

NAOMI MITSUHASHI, MD
TOMIO ONUMA, MD
RYUZO KAWAMORI, MD

From the Department of Medicine, Metabolism, and Endocrinology, Juntendo University, Tokyo, Japan.

Address correspondence to Naomi Mitsuhashi, Department of Medicine, Metabolism, and Endocrinology, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan 113-8421. E-mail: aquarius@xk9.so-net.ne.jp.

References

- Ostberg JE, Hurel SJ: Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients (Letter). *Diabetes Care* 26:961, 2003
- Mitsuhashi N, Onuma T, Kubo S, Takayanagi N, Honda M, Kawamori R: Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients. *Diabetes Care* 25:1308–1312, 2002
- Kannel WB: Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. *Am Heart J* 110:1100–1107, 1985
- Wilson PW, Castelli WP, Kannel WB: Coronary risk prediction in adults (the Framingham Heart Study). *Am J Cardiol* 59:91G–94G, 1987

- Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 16:434–444, 1993
- Ito H, Harano Y, Suzuki M, Hattori Y, Takeuchi M, Inada H, Inoue J, Kawamori R, Murase T, Ouchi Y, Umeda F, Nawata H, Orimo H, the Multiclinical Study for Diabetic Macroangiopathy Group: Risk factor analyses for macrovascular complication in nonobese NIDDM patients: Multiclinical Study for Diabetic Macroangiopathy (MSDN). *Diabetes* 45 (Suppl. 3): S19–S23, 1996
- Welborn TA, Knudman M, McCann V, Stanton K, Constable IJ: Clinical macrovascular disease in Caucoid diabetic subjects: logistic regression analysis of risk variables. *Diabetologia* 27:568–573, 1984
- Paisey RB, Arredondo G, Villalobos A, Lozano O, Guevara L, Kelly S: Association of differing dietary, metabolic, and clinical risk factors with macrovascular complications of diabetes: a prevalence study of 503 Mexican type 2 diabetic subjects. *Diabetes Care* 7:421–427, 1984
- Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. *Diabetes* 46:1354–1359, 1997
- DeStefano F, Ford ES, Newman J, Stevenson JM, Wetterhall SF, Anda RF, Vinicor F: Risk factors for coronary heart disease mortality among persons with diabetes. *Ann Epidemiol* 3:27–34, 1993

Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes

In a recent article by Desouza et al. (1), an improvement of brachial artery flow-mediated vasodilatation, a measurement indicating endothelium-dependent vasodilatation, was reported with both acute and prolonged sildenafil treatment. No measurements of endothelium-independent vasodilatation were performed. As the administration of sublingual nitroglycerin is mainly used to evaluate endothelium-independent vasodilatation, it is understandable that possible

side effects related to the concomitant use of sildenafil and nitroglycerine were the main reason for omitting this measurement. However, we believe that although the presented data are very interesting, they do not support the main conclusion of the article, namely that sildenafil improves endothelial function.

Sildenafil is a type-5 phosphodiesterase inhibitor that works directly at the vascular smooth muscle cell by preventing a breakdown of cyclic guanosine monophosphate (cGMP). Therefore, it should not affect the nitric oxide production and release by vascular endothelial cell, but it should enhance its action on the smooth muscle cell as it prolongs the action of the cGMP that is generated by the action of the nitric oxide.

The only way to dissect the action of sildenafil on the endothelial cell and the vascular smooth muscle cell is to perform measurements that evaluate both the endothelium-dependent and -independent vasodilation. In case the endothelium-dependent vasodilation improves while the endothelium-independent remains unchanged, a claim can be made that sildenafil affects the endothelial function. However, in case there is also an improvement in the endothelium-independent vasodilation. Therefore, we believe that the data should be interpreted as indicating a direct action of sildenafil on the smooth muscle cell, while an additional effect on the endothelial cell cannot be excluded. In case a disproportional improvement in the endothelium-independent measurement is noticed, it can be reasonably concluded that sildenafil mainly affects the smooth cell function. It should also be noted that such data have been provided in a previous study of healthy men (2). In that study, sildenafil administration increased sensitivity to local nitroglycerin (endothelial-independent vasodilatation) in the subjects' hand vein, resulting in the decrease in a 50% effective dose by about fourfold. In contrast, sildenafil did not significantly affect the maximal venodilatory response to acetylcholine or flow mediated artery vasodilatation (endothelial-dependent vasodilatation).

In conclusion, we believe that the data by Desouza et al. (1) provide significant information regarding the effect of sildenafil on the vasculature, but the conclusions should be modified to state that sildenafil improves vascular reactivity

(which encompasses both endothelium-dependent and -independent vasodilatation).

LALITA KHAODHIAR, MD
ARISTIDIS VEVES, MD

From the Joslin-Beth Israel Deaconess Foot Center, Microcirculation Lab, Department of Surgery, Boston, Massachusetts.

Address correspondence to Lalita Khaodhiar, MD, Joslin-Beth Israel Deaconess Foot Center, Microcirculation Lab, Department of Surgery, 1 Deaconess Rd., Palmer 317, Boston, MA 02215. E-mail: lkhaodhi@caregroup.harvard.edu.

References

1. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca V: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. *Diabetes Care* 25:1336-1339, 2002
2. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, Stein CM: The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. *Clin Pharmacol Ther* 70:270-279, 2001

Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes

Response to Khaodhiar and Veves

We appreciate the comments of Drs. Khaodhiar and Veves (1). We agree that in order to dissect the action of sildenafil on the endothelial cell and the vascular smooth muscle cell it is necessary to perform measurements that evaluate both endothelium-dependent and endothelium-independent vasodilatation. However, the latter requires the use of nitrates, which have the potential for serious (and potentially fatal) hypotension when used concomitantly with sildenafil. When giving us an investigational new drug exemption to carry out this study, the Food and Drug Administration specifically asked us not to use nitrates. Nevertheless, our results clearly demonstrate a beneficial effect of sildenafil on vascular reactivity that lasts well beyond the time expected from pharma-

cokinetic studies of the drug (2). Such treatment is thus able to overcome what is well recognized as a defect in endothelial function—even if possibly mediated through actions on smooth muscle cells.

We note that Dishy et al. (3) have demonstrated that sildenafil administration increased sensitivity to local nitroglycerin. However, their studies were carried out in healthy volunteers, whereas we studied patients with diabetes who may have had asymptomatic coronary artery disease. Much as we would like to do the study as suggested by Khaodhiar and Veves, our overriding concern is for patient safety (as it should be in all clinical research).

VIVIAN FONSECA, MD

From the Department of Medicine, Division of Endocrinology, Tulane University Medical Center, New Orleans, Louisiana.

Address correspondence to Vivian Fonseca, Tulane University Medical Center, Division of Endocrinology, Department of Medicine, 1430 Tulane Ave. (SL 53), New Orleans, LA 70112. E-mail: vfonseca@tulane.edu.

References

1. Khaodhiar L, Veves A: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes (Letter). *Diabetes Care* 26:962-963, 2003
2. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca V: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. *Diabetes Care* 25:1336-1339, 2002
3. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, Stein CM: The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. *Clin Pharmacol Ther* 70:270-279, 2001

Response to Gómez-Ulla et al.

We strongly disagree with the assertion of Gómez-Ulla et al. (1) that European protocols did not define any standards by which diabetic retinopathy screening programs should be assessed. Recently, Bachmann and Nelson (2) pooled the data from many available screening studies, dated up to 1996, and determined that retinal photography was the screening test of choice. In fact, the U.K. National Screening Com-

have contributed to the debate on the role of continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI). It is worth remembering that the only real benefit of CSII relates to the kinetics of delivery of subcutaneous insulin. We emphasized that all previous studies in which NPH insulin was used as the background insulin in MDI were of limited value because insulin glargine now provides a more physiological insulin profile (3). In addition, very few studies comparing CSII and MDI used a randomized, blinded treatment design. Without such a protocol, selection bias is very difficult to exclude. This problem is illustrated by the study cited by Cersosimo, which was neither randomized nor blinded (4). In this study, a significant difference in the two groups was present, both in the starting HbA_{1c} levels ($8.0 \pm 1.2\%$ for CSII and $8.6 \pm 1.0\%$ for MDI) and in the number of individuals in each group (35 for CSII and 50 for MDI). Without equivalence of groups at the initiation of the study, conclusions concerning their outcome parameters are difficult to make.

A second issue that is frequently overlooked when comparing CSII with MDI is the degree of interaction between the volunteer and the investigator's health care team. Initiating CSII requires extensive training in diet, carbohydrate counting, hypoglycemia awareness, attention to pump detail, and insulin delivery algorithms. This training and close follow-up are often more extensive than that which occurs with initiation of MDI. What per-

centage of the high success rate reported with CSII therapy is due to intensive educational and motivational training is unknown.

A third issue of concern is the cost of CSII versus MDI. We agree with Cersosimo, from the viewpoint of long-term cost analysis, that CSII may not be more costly than MDI. In fact, it may be cost effective. However, cost can be a major obstacle to the individual diabetic patient who may not have medical insurance and is therefore not be able to cover the immediate costs of CSII from his or her own resources. For many individuals in the U.S. currently without health insurance, starting CSII is not financially possible.

Our editorial attempted to make one major point—that additional data are urgently required before CSII can be broadly recommended over MDI in the general population of people with type 1 diabetes. Not only do we need studies utilizing insulin glargine in the MDI regimen, but these studies also need to be randomized and blinded to the greatest extent possible. Until such data become available, the decision to prescribe either CSII or MDI should be based on the criteria that we listed in our editorial. The health care team must determine which treatment modality has the greatest potential for benefit in each diabetic patient. K.M. Bolderman (5) appropriately states this concept in her excellent book on CSII by stating, "Discovering the character and source of motivation through careful

screening of the patient is the key to ensuring success in pump therapy."

DAVID S. SCHADE, MD¹
VIRGINIA VALENTINE, CNS, BC-ADM, CDE²

From the ¹Division of Endocrinology and Metabolism, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico; and the ²Clinical Associate Faculty—University of New Mexico College of Nursing, Diabetes Network, Albuquerque, New Mexico.

Address correspondence to David S. Schade, MD, University of New Mexico School of Medicine, Department of Internal Medicine/Division of Endocrinology and Metabolism, University of New Mexico Health Sciences Center, 5-ACC, Albuquerque, NM 87131. E-mail: dschade@salud.unm.edu.

References

1. Cersosimo E: Response to Schade: to pump or not to pump? (Letter). *Diabetes Care* 26:967, 2003
2. Schade DS, Valentine V: To pump or not to pump? (Editorial). *Diabetes Care* 25:2100–2102, 2002
3. Lepore M, Pampanelli S, Fanelli C: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. *Diabetes* 49:2142–2148, 2000
4. Cersosimo E, Jornsay D, Arce C, Rieff M, Feldman E, DeFronzo R: Improved clinical outcomes with intensive insulin pump therapy in type 1 diabetes (Abstract). *Diabetes* 51:A128, 2002
5. Bolderman KM: *Putting Your Patients on the Pump*. Alexandria, VA, ADA, 2002